Meeting News CoverageVideo

VIDEO: Systemic antibiotics increase C. difficile recurrence risk threefold

SAN DIEGO — In this exclusive video from DDW 2016, Monika Fischer, MD, from Indiana University, discusses her study which aimed to understand the long-term risk for recurrent Clostridium difficile infection following a successful fecal microbiota transplant.

Regarding the usefulness of prophylactic anti-C. diff antibiotic (vancomycin/metronidazole) or probiotic, “we could not make a conclusion from this study given the small sample size and the low number of recurrences on an antibiotic,” Fischer said. “However, what we could find is that the use of systemic antibiotics increased the risk of recurrence by threefold, so we can certainly tell our patients that the risk of overall recurrence is about 10% within 1 year or a year and a half following the fecal transplant. If they take an antibiotic, ... the risk will go up to 17% and if they can avoid the use of systemic antibiotics, then the risk is about 6%.”

Reference:

Fischer M, et al. Abstract #93. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosures : Fischer reports consulting for Rebiotix and Tetherex.

SAN DIEGO — In this exclusive video from DDW 2016, Monika Fischer, MD, from Indiana University, discusses her study which aimed to understand the long-term risk for recurrent Clostridium difficile infection following a successful fecal microbiota transplant.

Regarding the usefulness of prophylactic anti-C. diff antibiotic (vancomycin/metronidazole) or probiotic, “we could not make a conclusion from this study given the small sample size and the low number of recurrences on an antibiotic,” Fischer said. “However, what we could find is that the use of systemic antibiotics increased the risk of recurrence by threefold, so we can certainly tell our patients that the risk of overall recurrence is about 10% within 1 year or a year and a half following the fecal transplant. If they take an antibiotic, ... the risk will go up to 17% and if they can avoid the use of systemic antibiotics, then the risk is about 6%.”

Reference:

Fischer M, et al. Abstract #93. Presented at: Digestive Disease Week; May 21-24, 2016; San Diego.

Disclosures : Fischer reports consulting for Rebiotix and Tetherex.

    See more from Digestive Disease Week